InGel Therapeutics is pioneering innovative approaches to address retinal degeneration through engineered cell therapies that target neuroprotective pathways. The company has identified a unique cell state during the differentiation of retinal neurons, which allows for the generation of high-purity precursor cells. These cells, derived from fetal sources, are designed to proliferate while maintaining a specific lineage, thus avoiding the complications associated with heterogeneous stem cell populations. This advancement enables more effective therapeutic applications, as the precursor cells can be isolated for their neuroprotective secretome, facilitating the study of their mechanisms of action.

Additionally, InGel Therapeutics has developed a biomimetic hydrogel delivery platform that mimics the human vitreous, addressing the challenges of in vivo cell delivery. This hydrogel, composed of hyaluronic acid and gelatin, is engineered to provide a suitable microenvironment for retinal neurons, allowing for controlled injection and degradation that aligns with the natural processes in the eye. By optimizing the mechanical and spatial properties of the hydrogel, InGel aims to enhance the survival and integration of transplanted cells, ultimately improving outcomes for patients suffering from complex retinal diseases such as retinitis pigmentosa and age-related macular degeneration.

United States

InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.

InGel Therapeutics

Company Details